Vitality Watch

Dossier clinicaltrials trial early 21-aug-2026
Small or early-phase human trial or pilot study

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor

Key claim: A 12-week trial is testing whether 300 mg/day coenzyme Q10 improves CoQ10 status, glucose control, BDNF, myokines, and cognition in patients with MCI or Alzheimer’s disease plus hyperglycemia, stratified by sarcopenia risk.

Abstract

The aim of the study is to investigate the effects of coenzyme Q10 supplementation (150 mg twice daily; 300 mg/day for 12 weeks) on coenzyme Q10 status, glucose parameters, BDNF, myokines, and cognitive function in patients with mild cognitive impairment (MCI) or Alzheimer’s disease (AD) and hyperglycemia, either without sarcopenia risk or with pre-sarcopenia/sarcopenia risk.

Why this matters

A 12-week trial is testing whether 300 mg/day coenzyme Q10 improves CoQ10 status, glucose control, BDNF, myokines, and cognition in patients with MCI or Alzheimer’s disease plus hyperglycemia, stratified by sarcopenia risk.

Source

Link

Briefing card

Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
Stage: trial early · clinicaltrials · 21-aug-2026

A 12-week trial is testing whether 300 mg/day coenzyme Q10 improves CoQ10 status, glucose control, BDNF, myokines, and cognition in patients with MCI or Alzheimer's disease plus hyperglycemia, stratified by sarcopenia risk.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06040905

build build 880 · 2bcef25 · 2026-11-18